Back to Search
Start Over
Promoted Interaction of Nuclear Factor-κB With Demethylated Purinergic P2X3 Receptor Gene Contributes to Neuropathic Pain in Rats With Diabetes.
- Source :
-
Diabetes [Diabetes] 2015 Dec; Vol. 64 (12), pp. 4272-84. Date of Electronic Publication: 2015 Jun 30. - Publication Year :
- 2015
-
Abstract
- Painful diabetic neuropathy is a common complication of diabetes produced by mechanisms that as yet are incompletely defined. The aim of this study was to investigate the roles of nuclear factor-κB (NF-κB) in the regulation of purinergic receptor P2X ligand-gated ion channel 3 (P2X3R) plasticity in dorsal root ganglion (DRG) neurons of rats with painful diabetes. Here, we showed that hindpaw pain hypersensitivity in streptozocin-induced diabetic rats was attenuated by treatment with purinergic receptor antagonist suramin or A-317491. The expression and function of P2X3Rs was markedly enhanced in hindpaw-innervated DRG neurons in diabetic rats. The CpG (cytosine guanine dinucleotide) island in the p2x3r gene promoter region was significantly demethylated, and the expression of DNA methyltransferase 3b was remarkably downregulated in DRGs in diabetic rats. The binding ability of p65 (an active form of NF-κB) with the p2x3r gene promoter region and p65 expression were enhanced significantly in diabetes. The inhibition of p65 signaling using the NF-κB inhibitor pyrrolidine dithiocarbamate or recombinant lentiviral vectors designated as lentiviral vector-p65 small interfering RNA remarkably suppressed P2X3R activities and attenuated diabetic pain hypersensitivity. Insulin treatment significantly attenuated pain hypersensitivity and suppressed the expression of p65 and P2X3Rs. Our findings suggest that the p2x3r gene promoter DNA demethylation and enhanced interaction with p65 contributes to P2X3R sensitization and diabetic pain hypersensitivity.<br /> (© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.)
- Subjects :
- Animals
CpG Islands drug effects
DNA (Cytosine-5-)-Methyltransferases antagonists & inhibitors
DNA (Cytosine-5-)-Methyltransferases genetics
DNA (Cytosine-5-)-Methyltransferases metabolism
DNA Methylation drug effects
Diabetes Mellitus, Experimental drug therapy
Diabetic Neuropathies enzymology
Diabetic Neuropathies prevention & control
Female
Ganglia, Spinal drug effects
Ganglia, Spinal enzymology
Gene Expression Regulation drug effects
Hindlimb
Hypoglycemic Agents therapeutic use
Insulin therapeutic use
Nerve Tissue Proteins antagonists & inhibitors
Nerve Tissue Proteins genetics
Nerve Tissue Proteins metabolism
Neuralgia complications
Neuralgia prevention & control
Neurons drug effects
Neurons enzymology
Neurons metabolism
Promoter Regions, Genetic drug effects
Purinergic P2X Receptor Antagonists therapeutic use
RNA Interference
Rats, Sprague-Dawley
Receptors, Purinergic P2X3 chemistry
Receptors, Purinergic P2X3 genetics
Transcription Factor RelA agonists
Transcription Factor RelA antagonists & inhibitors
Transcription Factor RelA genetics
DNA Methyltransferase 3B
Diabetes Mellitus, Experimental complications
Diabetic Neuropathies metabolism
Epigenesis, Genetic drug effects
Ganglia, Spinal metabolism
Neuralgia metabolism
Receptors, Purinergic P2X3 metabolism
Transcription Factor RelA metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1939-327X
- Volume :
- 64
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Diabetes
- Publication Type :
- Academic Journal
- Accession number :
- 26130762
- Full Text :
- https://doi.org/10.2337/db15-0138